Agency for Health Care Administration (AHCA), Medicaid, Providers, Service utilization, Children, Adults, Program evaluation, Data collection, Data analysis, Health Maintenance Organizations, Medicaid Managed Care, MediPass, Penetration, Services research, Serious mental illness, Atypical anti-psychotic (AAP) medication, Cost analysis, Cost of care
Executive summaryBackground--Methods and population characteristics--Subject selection--Assignment to diagnostic groups--Standard Cost Rates--Pharmaceutical Definitions--Limitations--Results--Prevalence SMI diagnostic categories (as defined by community mental health and targeted case management service use) by AHCA area--Penetration of recommended drug classes for specific diagnostic groups--Penetration of anti-psychotics in adult schizophrenia diagnostic group--Penetration of anti-depressants in adult major depression diagnostic group--Penetration of preferred medications in target child/Adolescent diagnostic groups--Standard cost rates for all drug classes for each diagnostic group--Formulary analysis--Conclusions--References--Appendix 1: Description of problems with the statewide HMO pharmacy files--Appendix 2: Brief report of the Statewide Penetration and Standard Cost of Psychotropic Medications Study: A sub-study of the Agency for Health Care Administration (AHCA) project.
Was this content written or created while at USF?
Citation / Publisher Attribution
Agency for Health Care Administration Report Series; AHCA Series, 45 p.
Scholar Commons Citation
Murrin, Mary R., "Statewide Penetration and Standard Costs of Psychotropic Medications" (2003). Mental Health Law & Policy Faculty Publications. 504.